Insider · CIK 0001662411
James Warren Huff
Files at RETA (REATA PHARMACEUTICALS INC). First filing Mar 3, 2023, latest Mar 3, 2023.
In brief
James Warren Huff files SEC Form 4 as CEO and director at RETA (REATA PHARMACEUTICALS INC). Since Mar 3, 2023, James Warren Huff has reported 0 open-market buys worth $0 and 1 open-market sell worth $6.4M, the latest filed on Mar 3, 2023.
A track record needs three past buys with six months of prices behind them; James Warren Huff has 0, so none is measured yet.
The newest scored trade: sold $6.4M of RETA on Mar 2, 2023, filed Mar 3, 2023, scored 85 (strong).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 85Strong | REATA PHARMACEUTICALS INC | $6.4M 75,000 shares | -67% | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | RETA REATA PHARMACEUTICALS INC | CConversion Class A common stock | +75,000 | - | - | 111,158 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -8,104 | $81.49 | $660k | 103,054 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -12,132 | $82.20 | $997k | 90,922 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -9,660 | $83.31 | $805k | 81,262 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -7,439 | $84.33 | $627k | 73,823 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -6,395 | $85.25 | $545k | 67,428 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -3,475 | $86.44 | $300k | 63,953 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -4,034 | $87.61 | $353k | 59,919 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -12,826 | $88.59 | $1.1M | 47,093 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -5,742 | $89.49 | $514k | 41,351 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -4,623 | $90.57 | $419k | 36,728 | Mar 3, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -570 | $91.12 | $52k | 36,158 | Mar 3, 2023 |
| Mar 1, 2023 | RETA REATA PHARMACEUTICALS INC | CConversion Class B common stockderivative | -75,000 | - | - | 212,903 | Mar 3, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Class A common stock | +47,025 | $0.00 | $0 | 47,025 | Jan 4, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right-to-buy)derivative | +190,950 | $0.00 | $0 | 190,950 | Jan 4, 2023 |
Questions about James Warren Huff
Answered from the filings on this page, as of the latest one.
Is James Warren Huff buying or selling?
Not in the last 12 months. James Warren Huff's latest open-market trade on SEC Form 4 was sold $6.4M of RETA on Mar 2, 2023.
How did James Warren Huff's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Warren Huff has 0.
Where does James Warren Huff file Form 4?
James Warren Huff has filed Form 4 at RETA (REATA PHARMACEUTICALS INC) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.